Piramal to acquire Bayer's molecular imaging R&D portfolio: Mumbai-based publicly listed firm Piramal Healthcare Ltd. is to acquire the worldwide rights to the molecular imaging R&D portfolio of Berlin-based listed firm Bayer Pharma AG through its newly created subsidiary, Piramal Imaging SA. The deal, which includes certain milestone and royalty payments, gives Piramal the rights to florbetaben, a possible Alzheimer treatment. Under the agreement, Piramal will have the intellectual property (including patents, trademarks and know-how), worldwide development, marketing and distribution rights of the lead compound florbetaben as well as other clinical and pre-clinical assets of Bayer’s molecular imaging business.
Piramal estimates that the new class of PET imaging agents for Alzheimer's has a global market potential of up to $1.5 billion and is setting up a dedicated global commercial team for florbetaben. Core members of Bayer’s R&D team working on the portfolio will be joining Piramal Imaging, which will carry forward the development of florbetaben and take it through regulatory approval processes worldwide.
Are you a professional, freelancer or consulta More
Helplinelaw can set up your session with quality and experienced lawyers to discuss and resolve your legal matters. You can avail consultation in form of sending questions, phone call or webchat discussion More